



SUPPLEMENTARY DATA

Supplementary Figure 1. Change in serum AST, ALT and GGT levels relative to baseline




Reduction in serum ALT level is statistically significant between the empagliflozin and the control group

Supplementary Figure 2. The mean MRI-PDFF (liver fat) in liver segments I to VIII among 219 subjects with liver fat <5% on histopathology.




SUPPLEMENTARY DATA

Supplementary Figure 3. Correlation between changes in glycated haemoglobin (Δ HbA1C) and MRI-PDFF (Δ liver fat) after 20 weeks of empagliflozin treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease (solid circles) as compared with control group (solid triangles). One outlier patient not shown in the figure, who lost 25.2% liver fat in the empagliflozin group.




Supplementary Figure 4. Correlation between changes in MRI-PDFF (Δ liver fat) and body weight (Δ body weight) after 20 weeks of empagliflozin treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease (solid circles) as compared with control group (solid triangles). One outlier patient in the empagliflozin group not shown in the figure, who lost 25.2% liver fat.



SUPPLEMENTARY DATA

Supplementary Figure 5. Correlation between changes in serum ALT levels (Δ ALT) and body weight (Δ body weight) after 20 weeks of empagliflozin treatment in patients with type 2 diabetes and non-alcoholic fatty liver disease (solid circles) as compared with control group (solid triangles). One outlier patient in the empagliflozin group not shown in the figure, whose ALT increased by 80 U/L from baseline.



SUPPLEMENTARY DATA

Supplementary Table 1. Baseline demographic and biochemical characteristics

| | Control Group (n = 25) | Empagliflozin Group (n = 25) | p value |
|----------------------------|------------------------|------------------------------|---------|
| Demographics | | | |
| Age (years) | 49.1 (10.3) | 50.7 (12.8) | 0.762 |
| Female patients (%) | 8.0 (40.0) | 9.0 (41.1) | 0.952 |
| Weight (kg) | 81.2 (16.1) | 80.8 (13.0) | 0.791 |
| BMI (kg/m ²) | 29.4 (3.1) | 30.0 (3.8) | 0.597 |
| Duration of T2DM (years) | 6.8 (5.9) | 6.6 (5.3) | 0.946 |
| Seated SBP (mm/Hg) | 130 (19) | 124 (13) | 0.258 |
| Seated DBP (mm/Hg) | 81 (12) | 79 (10) | 0.885 |
| Biochemical profile | | | |
| Fasting Glucose (mg/dL) | 176 (56) | 173 (44) | 0.970 |
| HbA1C (%) | 9.1 (1.5) | 9.0 (1.0) | 0.743 |
| HbA1C (mmol/mol) | 76.1 (16.3) | 75.0 (10.9) | 0.804 |
| Serum Creatinine (mg/dL) | 0.9 (0.3) | 0.8 (0.2) | 0.517 |
| Total bilirubin (mg/dL) | 0.7 (0.3) | 0.7 (0.3) | 0.604 |
| AST (U/L) | 45.3 (24.3) | 44.6 (23.5) | 0.960 |
| ALT (U/L) | 65.3 (40.3) | 64.3 (20.2) | 0.650 |
| GGT (U/L) | 63.9 (45.3) | 65.8 (36.1) | 0.597 |
| Albumin (U/L) | 4.3 (0.3) | 4.2 (0.4) | 0.586 |
| Triglycerides (mg/dL) | 212 (115) | 201 (124) | 0.588 |
| HDL (mg/dL) | 45 (15) | 42 (12) | 0.537 |
| LDL (mg/dL) | 114 (30) | 112 (35) | 0.706 |

Data are means ± SD except where indicated. None of the baseline characteristics were significantly different between groups.

BMI, Body Mass Index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1C, glycated hemoglobin; AST, Aspartate Transaminase; ALT, Alanine Transaminase; GGT, Gamma-Glutamyl Transferase; HDL, High Density Lipoprotein; LDL, Low-Density Lipoprotein.

SUPPLEMENTARY DATA

Supplementary Table 2. Co-prescribed medications used by the study population

| S. No | Drugs | Control Group | | Empagliflozin Group | |
|-------|------------------------|---------------|---|---------------------|---|
| | | Percentage | Medicines/doses | Percentage | Medicines/doses |
| 1 | Metformin | 20/20 = 100 | 1725 (1000-2000) | 22/22 = 100 | 1520 (1000-2000) |
| 2 | DPP4-inhibitors | 14/20 = 70 | Sitagliptin 100 (7) Tenaligliptin 20 (6) Vildagliptin 100 (1) | 17/22 = 77.3 | Sitagliptin 100 (7). Tenaligliptin 20 (8) Vildagliptin 100 (1) Linagliptin 5 (1) |
| 3 | Sulfonylureas | 10/20 = 50 | Glimepiride 2-4 mg/d (9) Gliclazide 30 (1) | 12/22 = 54.5 | Glimepiride 2-4mg/d (10) Gliclazide 40-80mg (2) |
| 4 | Insulin | 1/20 = 5 | Pre-mix 30/70 (1) | 4/22 = 18.2 | Glargine (3) Pre-mix 30/70 (1) |
| 5 | Empagliflozin | 0 | - | 22/22 = 100 | 10 mg |
| 6 | Anti-lipidemics | 10/20 = 50 | Rosuvastatin 5-20 mg (5). Atorvastatin 10-20 mg (5) | 9/22 = 40.9 | Rosuvastatin 5-20 mg (7). Atorvastatin 10 (2) |
| 7 | Anti-hypertensives | 6/20 = 30 | Telmisartan 40 (1) Olmesartan 20 (1) Ramipril 5 (2) Telma 40 + HCTZ 12.5 (1). Telma 40 + Amlodipine 5 (1) | 9/22 = 41 | Telmisartan 20-80 (4). Olmesartan 40 (3). Losartan 50 (1). Telma 40 + Cilnidip 10 + HCTZ 12.5 (1) |
| 8 | Levothyroxine | 4/20 = 20 | 121.75 | 2/22 = 9 | 75 |
| 9 | Pregebalin | 4/20 = 20 | 75 | 1/22 = 4.5 | 75 |
| 10 | Proton pump inhibitors | 3/20 = 15 | Pantoprazole 40 (2). Omeprazole 20 (1) | 2/22 = 9 | Pantoprazole 40 (2) |
| 11 | Oral Cholecalceferol | 6/20 = 30 | 1000-2000 IU | 8/22 = 36.4 | 1000-2000 IU |

List of medications used by our patients in control and empagliflozin group. DPP-4, Dipeptidyl peptidase-4; HCTZ, hydrochlorthiazide; Telma, telmisartan; Cilnidip, cilnidipine.